Key result
Elevated CA125 and NT-proBNP linked to ~675% greater 1-year mortality risk versus low levels.
Why the study?
The study was designed to explore the prognostic value of serum CA125 combined with NT-proBNP in patients with acute heart failure.
Does the combination of CA125 and NT-proBNP predict 1-year all-cause death in patients with acute heart failure?
Cohort (n=213)
Does the combination of CA125 and NT-proBNP predict 1-year all-cause death in patients with acute heart failure?
The combination of elevated CA125 and NT-proBNP serves as a strong independent predictor of 1-year mortality in patients with acute heart failure, improving risk stratification.
Answers are grounded in this paper and cite their sources.
May aid high-risk identification in heart failure; leaves open incremental prognostic value and needs validation.
Background The objective was to explore the value of serum carbohydrate antigen 125 (CA125) combined with N-terminal pro B-type natriuretic peptide (NT-proBNP) in predicting the clinical prognosis of patients with acute heart failure (AHF).Methods We prospectively observed 213 patients with AHF. CA125 (U/ml) and NT-proBNP (pg/ml) were dichotomised based on ROC curve analysised prognostic cutpoints, and a variable with four groups was formed (CA125 and NT-proBNP): C1 = CA125 < 47.6 and NT-proBNP <3790 (n = 100); C2 = CA125 < 47.6 and NT-proBNP ≥3790 (n = 29); C3 = CA125 ≥ 47.6 and NT-proBNP < 3790 (n = 26); C4 = CA125 ≥ 47.6 and NT-proBNP ≥3790 (n = 58). Kaplan–Meier curve was drawn and multivariate COX regression analysis was performed to analyse the prognostic efficacy of CA125 combined with NT-ProBNP in patients with AHF.Results The levels of CA125 and NT-proBNP in death group were obviously higher than those in non-death group [56.20 (45.70, 78.00) vs 31.10 (19.48, 47.68), p < 0.001; 5619.00 (2924.00, 10066.00) vs 2203.00 (1460.50, 5070.25), p < 0.001]. The ROC curve showed that the best cut-off values of CA125 and NT-proBNP for predicting the prognosis of AHF were 47.6 and 3790, respectively. Multivariate COX regression analysis showed that CA125 ≥ 47.6 and NT-proBNP ≥ 3790 were independent predictors of 1-year all-cause death in patients with AHF (HR = 3.05, 95%CI: 1.50–6.20, p = 0.002) and (HR = 2.34, 95%CI: 1.19–4.61, p = 0.014). At 12 months, 55 deaths (25.8%) were identified. The cumulative rate of mortality was highest for patients in C4 (56.9%), intermediate for C2 and C3 (24.1% and 34.6%, respectively), and lowest for C1 (6.0%), and p-value for trend <0.05. After adjusting for established clinical risk factors, compared with C1: C2 (HR = 4.58, 95%CI: 1.53–13.77, p = 0.007), C3 (HR = 5.24, 95%CI: 1.85–14.82, p = 0.002), C4 (HR = 7.75, 95%CI: 3.09–19.45, p < 0.001).Conclusion Elevated CA125 is an independent predictor of poor prognosis in patients with AHF, and combined with NT-proBNP can improve the efficiency of risk identification.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2020) conducted a cohort in Acute heart failure (n=213). Elevated CA125 (≥47.6 U/ml) and NT-proBNP (≥3790 pg/ml) vs. CA125 <47.6 U/ml and NT-proBNP <3790 pg/ml was evaluated on 1-year all-cause death (HR 7.75, 95% CI 3.09-19.45, p=<0.001). Elevated CA125 combined with NT-proBNP was associated with a higher risk of 1-year all-cause death compared to low levels of both.
Synapse has enriched 10 related papers. Consider them for comparative context: